Kathleen Mary Ellen Gallagher, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mumps | 8 | 2014 | 64 | 1.450 |
Why?
|
Disease Outbreaks | 13 | 2023 | 1772 | 0.990 |
Why?
|
Measles | 5 | 2022 | 168 | 0.890 |
Why?
|
Population Surveillance | 13 | 2017 | 2616 | 0.860 |
Why?
|
Measles-Mumps-Rubella Vaccine | 6 | 2013 | 66 | 0.850 |
Why?
|
Immunotherapy, Adoptive | 12 | 2024 | 1270 | 0.720 |
Why?
|
Behavioral Risk Factor Surveillance System | 4 | 2007 | 199 | 0.680 |
Why?
|
Ethiopia | 8 | 2023 | 495 | 0.580 |
Why?
|
Measles virus | 2 | 2016 | 68 | 0.570 |
Why?
|
Mumps Vaccine | 2 | 2014 | 17 | 0.560 |
Why?
|
Vaccination | 9 | 2022 | 3278 | 0.560 |
Why?
|
Public Health Administration | 4 | 2007 | 240 | 0.560 |
Why?
|
Sentinel Surveillance | 2 | 2018 | 281 | 0.550 |
Why?
|
Immunization Programs | 5 | 2017 | 260 | 0.550 |
Why?
|
Risk-Taking | 5 | 2007 | 986 | 0.530 |
Why?
|
Homosexuality, Male | 7 | 2007 | 1240 | 0.520 |
Why?
|
Laboratories | 2 | 2021 | 463 | 0.510 |
Why?
|
Immunization, Secondary | 2 | 2012 | 340 | 0.470 |
Why?
|
Immunization | 2 | 2017 | 1256 | 0.460 |
Why?
|
CD4-Positive T-Lymphocytes | 7 | 2012 | 4386 | 0.420 |
Why?
|
Health Behavior | 3 | 2017 | 2636 | 0.420 |
Why?
|
Multiple Myeloma | 3 | 2023 | 5181 | 0.380 |
Why?
|
Jews | 1 | 2012 | 385 | 0.380 |
Why?
|
Drug Resistance, Bacterial | 1 | 2018 | 1035 | 0.360 |
Why?
|
Interferon-alpha | 2 | 2012 | 895 | 0.330 |
Why?
|
Vaccines | 1 | 2017 | 822 | 0.320 |
Why?
|
Epitopes, T-Lymphocyte | 4 | 2021 | 880 | 0.320 |
Why?
|
HLA-DR1 Antigen | 1 | 2007 | 12 | 0.310 |
Why?
|
Urban Health | 2 | 2007 | 547 | 0.300 |
Why?
|
Immunologic Memory | 4 | 2010 | 1348 | 0.290 |
Why?
|
Measles Vaccine | 2 | 2017 | 76 | 0.280 |
Why?
|
Human papillomavirus 18 | 1 | 2007 | 128 | 0.280 |
Why?
|
HLA-DR Antigens | 2 | 2008 | 645 | 0.280 |
Why?
|
New York | 6 | 2014 | 886 | 0.270 |
Why?
|
Receptors, Antigen, T-Cell | 4 | 2024 | 2540 | 0.260 |
Why?
|
Human papillomavirus 16 | 1 | 2007 | 262 | 0.260 |
Why?
|
Poliovirus Vaccines | 2 | 2017 | 18 | 0.260 |
Why?
|
Hepatitis B | 2 | 2009 | 695 | 0.240 |
Why?
|
Poliomyelitis | 2 | 2017 | 103 | 0.230 |
Why?
|
Daunorubicin | 1 | 2023 | 158 | 0.230 |
Why?
|
T-Lymphocytes | 10 | 2023 | 10180 | 0.220 |
Why?
|
Hepatitis C | 3 | 2009 | 1591 | 0.220 |
Why?
|
Central Nervous System Neoplasms | 2 | 2022 | 895 | 0.210 |
Why?
|
Leukemia, Myeloid, Acute | 3 | 2023 | 3523 | 0.200 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 1378 | 0.200 |
Why?
|
Lymphoma | 2 | 2022 | 1877 | 0.200 |
Why?
|
HIV Infections | 8 | 2010 | 16718 | 0.200 |
Why?
|
Influenza Vaccines | 2 | 2012 | 738 | 0.190 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 297 | 0.180 |
Why?
|
Antineoplastic Agents | 1 | 2023 | 13695 | 0.180 |
Why?
|
Influenza, Human | 2 | 2012 | 1479 | 0.180 |
Why?
|
Adolescent | 23 | 2019 | 85781 | 0.180 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2019 | 40 | 0.180 |
Why?
|
Communicable Diseases | 2 | 2022 | 880 | 0.180 |
Why?
|
Antibodies, Viral | 4 | 2022 | 3176 | 0.170 |
Why?
|
Sexual Behavior | 2 | 2006 | 2057 | 0.170 |
Why?
|
Anti-Bacterial Agents | 1 | 2018 | 7181 | 0.170 |
Why?
|
Hematologic Neoplasms | 2 | 2022 | 1832 | 0.170 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2024 | 4479 | 0.170 |
Why?
|
Age Distribution | 4 | 2017 | 2902 | 0.160 |
Why?
|
Flow Cytometry | 4 | 2021 | 5974 | 0.160 |
Why?
|
Humans | 66 | 2024 | 744343 | 0.160 |
Why?
|
Mass Screening | 3 | 2009 | 5255 | 0.160 |
Why?
|
Open Reading Frames | 1 | 2021 | 810 | 0.150 |
Why?
|
Neurotoxicity Syndromes | 1 | 2022 | 290 | 0.150 |
Why?
|
Disease Notification | 2 | 2013 | 97 | 0.150 |
Why?
|
Security Measures | 1 | 2018 | 77 | 0.150 |
Why?
|
Hepatitis C, Chronic | 3 | 2012 | 1031 | 0.150 |
Why?
|
Infant | 12 | 2017 | 35136 | 0.150 |
Why?
|
Epidemics | 1 | 2023 | 523 | 0.150 |
Why?
|
Cholera | 1 | 2023 | 785 | 0.140 |
Why?
|
Specimen Handling | 1 | 2021 | 694 | 0.140 |
Why?
|
Piperazines | 1 | 2006 | 2488 | 0.130 |
Why?
|
Contact Tracing | 2 | 2022 | 273 | 0.130 |
Why?
|
Capacity Building | 1 | 2018 | 248 | 0.130 |
Why?
|
Antigens, CD19 | 3 | 2022 | 380 | 0.130 |
Why?
|
Public Health | 3 | 2022 | 2603 | 0.120 |
Why?
|
Rubella | 2 | 2011 | 48 | 0.120 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2021 | 1366 | 0.120 |
Why?
|
Adult | 28 | 2022 | 214055 | 0.120 |
Why?
|
Child, Preschool | 12 | 2023 | 41006 | 0.120 |
Why?
|
Young Adult | 12 | 2019 | 56430 | 0.120 |
Why?
|
Hepatitis A Vaccines | 2 | 2011 | 29 | 0.120 |
Why?
|
Religion | 1 | 2017 | 356 | 0.120 |
Why?
|
Male | 34 | 2023 | 350118 | 0.120 |
Why?
|
Hepatitis A | 2 | 2011 | 133 | 0.110 |
Why?
|
Biological Products | 1 | 2022 | 860 | 0.110 |
Why?
|
Antigens, Neoplasm | 2 | 2019 | 1988 | 0.110 |
Why?
|
Syphilis | 2 | 2005 | 227 | 0.110 |
Why?
|
Epitopes | 2 | 2012 | 2571 | 0.110 |
Why?
|
Orchitis | 1 | 2012 | 35 | 0.110 |
Why?
|
New Jersey | 1 | 2012 | 290 | 0.110 |
Why?
|
Hepatitis A Antibodies | 1 | 2011 | 18 | 0.100 |
Why?
|
Aviation | 1 | 2011 | 42 | 0.100 |
Why?
|
Child | 15 | 2017 | 77709 | 0.100 |
Why?
|
Peptides | 3 | 2021 | 4409 | 0.100 |
Why?
|
Health Personnel | 3 | 2021 | 3218 | 0.100 |
Why?
|
United States | 19 | 2022 | 69872 | 0.100 |
Why?
|
Immunization Schedule | 1 | 2012 | 221 | 0.100 |
Why?
|
Poliovirus | 1 | 2012 | 109 | 0.100 |
Why?
|
Neoplastic Stem Cells | 1 | 2019 | 1376 | 0.100 |
Why?
|
Middle Aged | 20 | 2022 | 213383 | 0.100 |
Why?
|
Proteome | 1 | 2021 | 1799 | 0.100 |
Why?
|
Mumps virus | 1 | 2010 | 24 | 0.100 |
Why?
|
Female | 28 | 2023 | 380194 | 0.100 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 1596 | 0.090 |
Why?
|
Public Sector | 1 | 2012 | 265 | 0.090 |
Why?
|
Orthomyxoviridae | 1 | 2012 | 156 | 0.090 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2010 | 130 | 0.090 |
Why?
|
Health Education | 1 | 2017 | 1056 | 0.090 |
Why?
|
Sexually Transmitted Diseases, Viral | 1 | 2010 | 40 | 0.090 |
Why?
|
Tuberculin | 1 | 2009 | 66 | 0.090 |
Why?
|
Cost of Illness | 2 | 2017 | 1859 | 0.090 |
Why?
|
Sex Distribution | 2 | 2012 | 2297 | 0.090 |
Why?
|
Leukocytes, Mononuclear | 2 | 2022 | 1836 | 0.090 |
Why?
|
Urban Population | 1 | 2017 | 2021 | 0.080 |
Why?
|
Tetanus Toxoid | 1 | 2009 | 193 | 0.080 |
Why?
|
Cambodia | 1 | 2009 | 191 | 0.080 |
Why?
|
AIDS Serodiagnosis | 1 | 2010 | 184 | 0.080 |
Why?
|
Glioblastoma | 1 | 2024 | 3481 | 0.080 |
Why?
|
Washington | 1 | 2009 | 313 | 0.080 |
Why?
|
Peritoneal Dialysis | 1 | 2009 | 146 | 0.080 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2009 | 157 | 0.080 |
Why?
|
HLA-A2 Antigen | 1 | 2008 | 213 | 0.080 |
Why?
|
Acquired Immunodeficiency Syndrome | 4 | 2005 | 2232 | 0.080 |
Why?
|
Injections, Subcutaneous | 1 | 2009 | 666 | 0.080 |
Why?
|
Hepatitis, Viral, Human | 1 | 2008 | 138 | 0.080 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2007 | 1873 | 0.080 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2010 | 323 | 0.080 |
Why?
|
Peritonitis | 1 | 2009 | 365 | 0.070 |
Why?
|
Incidence | 6 | 2017 | 20947 | 0.070 |
Why?
|
Disease Transmission, Infectious | 1 | 2012 | 547 | 0.070 |
Why?
|
Lymphocyte Activation | 3 | 2019 | 5524 | 0.070 |
Why?
|
Immunoassay | 1 | 2010 | 752 | 0.070 |
Why?
|
Cognition | 1 | 2023 | 6770 | 0.070 |
Why?
|
Travel | 1 | 2011 | 788 | 0.070 |
Why?
|
Caregivers | 1 | 2017 | 2094 | 0.070 |
Why?
|
California | 1 | 2009 | 1402 | 0.060 |
Why?
|
Unsafe Sex | 1 | 2007 | 220 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2017 | 3589 | 0.060 |
Why?
|
Hepacivirus | 1 | 2012 | 1379 | 0.060 |
Why?
|
Geography | 1 | 2007 | 669 | 0.060 |
Why?
|
Infant, Newborn | 3 | 2016 | 25625 | 0.060 |
Why?
|
Schools | 1 | 2012 | 1433 | 0.060 |
Why?
|
Aged | 12 | 2023 | 163280 | 0.060 |
Why?
|
Papillomavirus Vaccines | 2 | 2007 | 491 | 0.060 |
Why?
|
Sulfones | 1 | 2006 | 437 | 0.060 |
Why?
|
Substance Abuse, Intravenous | 2 | 2007 | 525 | 0.060 |
Why?
|
Guam | 2 | 2013 | 30 | 0.060 |
Why?
|
Health Care Costs | 2 | 2014 | 3209 | 0.060 |
Why?
|
Aminoglycosides | 1 | 2023 | 162 | 0.060 |
Why?
|
Oncogene Proteins, Viral | 1 | 2004 | 362 | 0.060 |
Why?
|
HIV Antibodies | 1 | 2010 | 1322 | 0.050 |
Why?
|
B-Cell Maturation Antigen | 1 | 2023 | 140 | 0.050 |
Why?
|
Purines | 1 | 2006 | 594 | 0.050 |
Why?
|
Sanitation | 1 | 2023 | 93 | 0.050 |
Why?
|
Emigrants and Immigrants | 1 | 2009 | 522 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2019 | 7880 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 3923 | 0.050 |
Why?
|
Cells, Cultured | 2 | 2009 | 19229 | 0.050 |
Why?
|
Rubella virus | 2 | 2011 | 11 | 0.050 |
Why?
|
Cytarabine | 1 | 2023 | 692 | 0.050 |
Why?
|
Immunoenzyme Techniques | 1 | 2004 | 1799 | 0.050 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2005 | 657 | 0.050 |
Why?
|
Genotype | 1 | 2016 | 12951 | 0.050 |
Why?
|
Thiazoles | 1 | 2008 | 1483 | 0.050 |
Why?
|
Program Evaluation | 1 | 2009 | 2488 | 0.050 |
Why?
|
Pneumococcal Infections | 1 | 2005 | 497 | 0.050 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2019 | 87 | 0.040 |
Why?
|
Reference Values | 1 | 2007 | 4982 | 0.040 |
Why?
|
Sexually Transmitted Diseases | 1 | 2005 | 624 | 0.040 |
Why?
|
Logistic Models | 2 | 2017 | 13408 | 0.040 |
Why?
|
Macrophage Activation | 1 | 2022 | 558 | 0.040 |
Why?
|
Age Factors | 2 | 2012 | 18370 | 0.040 |
Why?
|
Cytokines | 3 | 2022 | 7322 | 0.040 |
Why?
|
Administration, Oral | 1 | 2006 | 3913 | 0.040 |
Why?
|
Environmental Exposure | 1 | 2012 | 4234 | 0.040 |
Why?
|
Attitude to Health | 1 | 2007 | 2052 | 0.040 |
Why?
|
Prospective Studies | 2 | 2022 | 53288 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 2010 | 4665 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2007 | 5078 | 0.040 |
Why?
|
Kidney Failure, Chronic | 1 | 2009 | 2538 | 0.040 |
Why?
|
CD4 Lymphocyte Count | 1 | 2003 | 2559 | 0.040 |
Why?
|
Pyrimidines | 1 | 2008 | 2942 | 0.030 |
Why?
|
Treatment Outcome | 4 | 2019 | 63114 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2017 | 25043 | 0.030 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2019 | 1369 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2021 | 1284 | 0.030 |
Why?
|
Prevalence | 3 | 2010 | 15226 | 0.030 |
Why?
|
Reproducibility of Results | 3 | 2021 | 19905 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2024 | 9239 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2019 | 1880 | 0.030 |
Why?
|
Patient Selection | 1 | 2007 | 4215 | 0.030 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2008 | 2988 | 0.030 |
Why?
|
Community-Institutional Relations | 2 | 2005 | 204 | 0.030 |
Why?
|
Risk Factors | 5 | 2023 | 72290 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2009 | 10481 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2022 | 3206 | 0.030 |
Why?
|
Kinetics | 1 | 2021 | 6473 | 0.030 |
Why?
|
Health Promotion | 1 | 2005 | 2205 | 0.030 |
Why?
|
Amino Acid Sequence | 2 | 2021 | 13815 | 0.030 |
Why?
|
Natural Cytotoxicity Triggering Receptor 1 | 1 | 2012 | 27 | 0.030 |
Why?
|
Neoplasms | 1 | 2022 | 21683 | 0.030 |
Why?
|
Papillomavirus Infections | 1 | 2004 | 1587 | 0.030 |
Why?
|
Massachusetts | 2 | 2003 | 8663 | 0.030 |
Why?
|
Rubella Vaccine | 1 | 2011 | 22 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 1 | 2008 | 5535 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 1978 | 0.030 |
Why?
|
HEK293 Cells | 1 | 2021 | 4204 | 0.030 |
Why?
|
Crowding | 1 | 2013 | 145 | 0.030 |
Why?
|
Biotinylation | 1 | 2012 | 179 | 0.030 |
Why?
|
Cell Growth Processes | 1 | 2012 | 399 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2019 | 3557 | 0.020 |
Why?
|
Viral Load | 2 | 2012 | 3299 | 0.020 |
Why?
|
Surface Plasmon Resonance | 1 | 2012 | 274 | 0.020 |
Why?
|
Antibody-Producing Cells | 1 | 2010 | 143 | 0.020 |
Why?
|
Molecular Conformation | 1 | 2012 | 563 | 0.020 |
Why?
|
Mexican Americans | 1 | 2011 | 166 | 0.020 |
Why?
|
Alleles | 1 | 2021 | 6933 | 0.020 |
Why?
|
Seroepidemiologic Studies | 1 | 2011 | 401 | 0.020 |
Why?
|
Alanine Transaminase | 1 | 2012 | 592 | 0.020 |
Why?
|
Time Factors | 2 | 2012 | 40075 | 0.020 |
Why?
|
Los Angeles | 1 | 2010 | 238 | 0.020 |
Why?
|
Peritoneal Cavity | 1 | 2009 | 148 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2009 | 6773 | 0.020 |
Why?
|
U937 Cells | 1 | 2009 | 268 | 0.020 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2010 | 224 | 0.020 |
Why?
|
Florida | 1 | 2010 | 435 | 0.020 |
Why?
|
Hepatitis C Antigens | 1 | 2008 | 34 | 0.020 |
Why?
|
Risk Assessment | 2 | 2007 | 23338 | 0.020 |
Why?
|
Hepatitis C Antibodies | 1 | 2008 | 145 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2012 | 1475 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2004 | 9648 | 0.020 |
Why?
|
Protein Binding | 1 | 2019 | 9386 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2003 | 4256 | 0.020 |
Why?
|
Hepatitis B Vaccines | 1 | 2008 | 194 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2012 | 1200 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2618 | 0.020 |
Why?
|
Gene Expression | 1 | 2019 | 7799 | 0.020 |
Why?
|
Mice | 3 | 2021 | 81183 | 0.020 |
Why?
|
Models, Immunological | 1 | 2008 | 527 | 0.020 |
Why?
|
Puerto Rico | 1 | 2007 | 356 | 0.020 |
Why?
|
Immunity | 1 | 2012 | 1012 | 0.020 |
Why?
|
Poisson Distribution | 1 | 2007 | 513 | 0.020 |
Why?
|
India | 1 | 2011 | 2197 | 0.020 |
Why?
|
Temperature | 1 | 2012 | 2206 | 0.020 |
Why?
|
Sampling Studies | 1 | 2007 | 623 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2023 | 21746 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2011 | 1405 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2019 | 12354 | 0.020 |
Why?
|
Viremia | 1 | 2008 | 736 | 0.020 |
Why?
|
Developing Countries | 1 | 2017 | 2815 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2012 | 3846 | 0.020 |
Why?
|
Nutrition Surveys | 1 | 2011 | 1660 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2008 | 1100 | 0.010 |
Why?
|
Parents | 1 | 2017 | 3407 | 0.010 |
Why?
|
Killer Cells, Natural | 1 | 2012 | 2133 | 0.010 |
Why?
|
New York City | 1 | 2005 | 710 | 0.010 |
Why?
|
Cities | 1 | 2005 | 513 | 0.010 |
Why?
|
Communication | 1 | 2017 | 3749 | 0.010 |
Why?
|
Students | 1 | 2013 | 1654 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11524 | 0.010 |
Why?
|
Retrospective Studies | 4 | 2019 | 77449 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8388 | 0.010 |
Why?
|
Vulvar Neoplasms | 1 | 2004 | 272 | 0.010 |
Why?
|
Vaccines, Synthetic | 1 | 2004 | 634 | 0.010 |
Why?
|
Aged, 80 and over | 3 | 2012 | 57776 | 0.010 |
Why?
|
Models, Molecular | 1 | 2012 | 5456 | 0.010 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2019 | 5442 | 0.010 |
Why?
|
Models, Genetic | 1 | 2012 | 3494 | 0.010 |
Why?
|
Family | 1 | 2012 | 3147 | 0.010 |
Why?
|
Cohort Studies | 3 | 2012 | 40561 | 0.010 |
Why?
|
Animals | 3 | 2021 | 168757 | 0.010 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2004 | 387 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 3870 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18029 | 0.010 |
Why?
|
Health Services | 1 | 2005 | 758 | 0.010 |
Why?
|
Up-Regulation | 1 | 2009 | 4217 | 0.010 |
Why?
|
Risk | 1 | 2012 | 9687 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2013 | 7785 | 0.010 |
Why?
|
Viral Vaccines | 1 | 2004 | 636 | 0.010 |
Why?
|
Program Development | 1 | 2005 | 1316 | 0.010 |
Why?
|
Prognosis | 1 | 2019 | 29063 | 0.010 |
Why?
|
Papillomaviridae | 1 | 2004 | 1119 | 0.010 |
Why?
|
Acute Disease | 1 | 2008 | 7149 | 0.010 |
Why?
|
Patient Compliance | 1 | 2007 | 2684 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2008 | 9734 | 0.010 |
Why?
|
Models, Biological | 1 | 2012 | 9583 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2010 | 14722 | 0.010 |
Why?
|
Medical Records | 1 | 2000 | 1413 | 0.010 |
Why?
|
Pneumonia, Pneumocystis | 1 | 1995 | 249 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2009 | 8428 | 0.010 |
Why?
|
Candidiasis | 1 | 1995 | 366 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2004 | 18111 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2005 | 5137 | 0.000 |
Why?
|
Medicaid | 1 | 2000 | 2736 | 0.000 |
Why?
|
Survivors | 1 | 1995 | 2291 | 0.000 |
Why?
|
Registries | 1 | 2000 | 8089 | 0.000 |
Why?
|
Tuberculosis | 1 | 1995 | 1912 | 0.000 |
Why?
|
Boston | 1 | 1995 | 9313 | 0.000 |
Why?
|